ReviewACS pharmacology & translational science2026
Emerging RNA-Based Therapeutic Strategies for Inflammatory Ophthalmic Disorders of the Anterior Segment: Mechanistic Insights and Translational Potential.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anterior segment ocular inflammatory disorders, including conjunctivitis, keratitis, scleritis, dry eye disease, and anterior uveitis, represent a major cause of visual impairment worldwide. Conventional pharmacological therapies such as antihistamines, corticosteroids, and immunomodulators primarily provide symptomatic relief but are limited by their adverse effects, poor long-term efficacy, and lack of disease-modifying potential. In this review, RNA-based therapeutics are discussed in detail, emerging as promising and targeted approaches for modulating the molecular mechanisms underlying ocular anterior segment inflammatory conditions. These strategies include small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense oligonucleotides (ASOs), messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA), each offering distinct mechanisms to regulate gene expression and inflammatory signaling pathways. RNA therapeutics enable precise silencing or modulation of key mediators such as cytokines, transcription factors, and immune regulators involved in Th2-driven and immune-mediated inflammatory responses. Recent advances in nanotechnology-based delivery systems, including lipid nanoparticles, polymeric carriers, and viral vectors, have significantly improved RNA stability, bioavailability, and targeted ocular delivery. Despite these advances, challenges such as ocular surface barriers, rapid tear clearance, enzymatic degradation, off-target effects, and potential immunogenicity remain significant hurdles. Overall, RNA-based therapies hold substantial potential as next-generation, disease-modifying treatments for anterior segment inflammatory disorders, including DED, warranting further translational and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.